Ramucirumab for the treatment of gastroesophageal cancers

INTRODUCTION: In 2014, the U.S. Food and Drug Administration (FDA) approved ramucirumab for use in the second line setting of advanced or metastatic, gastric or gastroesophageal adenocarcinoma (GEAC) based on the result of Phase III clinical trials; REGARD and RAINBOW. AREAS COVERED: We briefly revi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Expert Opin Orphan Drugs
Asıl Yazarlar: Shimodaira, Y., Elimova, E., Wadhwa, R., Shiozaki, H., Charalampakis, N., Planjery, V., Rogers, J.E., Song, S., Ajani, J.A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2015
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5001688/
https://ncbi.nlm.nih.gov/pubmed/27570714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1040390
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller